Closing out 2024 and Looking Ahead to 2025
As we approach the close of this year’s legislative calendar, the urgency surrounding the federal budget process cannot be overstated. If action is not taken before December 20, the federal government will shut down. At OCRA, we understand that every dollar allocated to cancer research represents hope for millions of patients, survivors, and their families.
That’s why we are calling on Congress to finalize the 2025 budget and prioritize life-saving investments in cancer research. Appropriations for research at institutions like the National Cancer Institute (NCI) and the Department of Defense’s Ovarian Cancer Research Program (OCRP) are the forces of innovation that fuel clinical trials, cutting-edge discoveries, and public health initiatives that save lives. Delays, uncertainty, and funding cuts have a direct impact, including fewer research grants awarded and stalled progress on new therapies. OCRA will continue pressing Congress to finalize the 2025 appropriations process and prioritize cancer funding. Add your voice now.
Navigating the Transition: New Leadership and Appointments
As we continue our advocacy efforts into the new year, we are closely monitoring appointments within the new administration. Leadership changes across federal agencies such as the Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and other key entities will shape the future of health policy.
These appointees will bring new opportunities and challenges, and OCRA is prepared to engage with these leaders to underscore the importance of sustained funding and equitable access to care for ovarian and all gynecologic cancer patients. We are already tracking appointments and working to establish relationships that will strengthen our advocacy impact in 2025 and beyond.
As always, thank you for standing with us and adding your voice to the effort.
Together, we can make a difference!
Chad Ramsey, Vice President, Policy, OCRA
